These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 27100305

  • 1. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G, Minet V, Mullier F, Michaux I.
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
    [Abstract] [Full Text] [Related]

  • 2. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
    Tardy-Poncet B, Wolf M, Lasne D, Bauters A, Ffrench P, Elalamy I, Tardy B.
    Intensive Care Med; 2009 Aug; 35(8):1449-53. PubMed ID: 19350215
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF, Pindur G, Stephan B, Mörsdorf S, Mertzlufft F, Kroll H, Wenzel E, Seyfert UT.
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B, Tardy B, Reynaud J, Mahul P, Mismetti P, Mazet E, Guyotat D.
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [Abstract] [Full Text] [Related]

  • 7. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN, Gallus A.
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [Abstract] [Full Text] [Related]

  • 8. Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
    Castelino RL, Maddula M, Tarafdar S, Sud K, Kairaitis L.
    Thromb Res; 2019 Aug; 180():70-73. PubMed ID: 31229923
    [Abstract] [Full Text] [Related]

  • 9. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B, Zenz W, Rettenbacher A, Covi P, Kurnik K, Kroll H, Grubbauer HM, Muntean W.
    Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
    [Abstract] [Full Text] [Related]

  • 10. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
    Verdy E, Debrix I, Benomar A, Becker A, Flahault A.
    Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
    [Abstract] [Full Text] [Related]

  • 11. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani HN.
    Thromb Res; 2006 May; 117(5):507-15. PubMed ID: 15907979
    [Abstract] [Full Text] [Related]

  • 12. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S, Manhas AH, Udden M, Rice L.
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [Abstract] [Full Text] [Related]

  • 13. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI, Markham A.
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [Abstract] [Full Text] [Related]

  • 14. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR, Hickton C, Henderson S, Patton WN.
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [Abstract] [Full Text] [Related]

  • 15. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E, Bauersachs R.
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [Abstract] [Full Text] [Related]

  • 16. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract] [Full Text] [Related]

  • 17. Heparin-induced thrombocytopaenia.
    Prince M, Wenham T.
    Postgrad Med J; 2018 Aug; 94(1114):453-457. PubMed ID: 30126928
    [Abstract] [Full Text] [Related]

  • 18. Danaparoid sodium.
    Acostamadiedo JM, Iyer UG, Owen J.
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [Abstract] [Full Text] [Related]

  • 19. Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia.
    Tardy-Poncet B, Combe M, Piot M, Chapelle C, Akrour M, Tardy B.
    Thromb Haemost; 2013 Mar; 109(3):504-9. PubMed ID: 23328916
    [Abstract] [Full Text] [Related]

  • 20. [Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia].
    Brémaud M, De Maistre E, Junke E, Guerci A, Lalot JM, Longrois D, Lecompte T, Meistelman C.
    Ann Fr Anesth Reanim; 2004 Feb; 23(1):50-5. PubMed ID: 14980323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.